Prostate‐specific membrane antigen (PSMA) can provide a prostate cancer (PCa) detection approach in positron emission tomography (PET) using Food and Drug Administration (FDA)‐approved PSMA‐11 peptide. There are some studies evaluated magnetic‐nanoprobes for PSMA detection by MRI, using non‐FDA‐approved ligands including antibodies or peptides, which are not as specific as PSMA‐11.
To assess targeted iron oxide nanoparticles (IONPs) by PSMA‐11 peptides as a potential specific nano‐molecular probes to investigate a PSMA + PCa‐xenograft model by MRI.
Coated IONPs with Carboxymethylated‐dextran (DNPs) and with bovine serum albumin (BNPs), as well as, targeted DNPs with PSMA‐11‐HYNIC peptide (TDNPs) and targeted BNPs with PSMA‐11‐HBED peptide (TBNPs) were injected intravenously with dose 2.8 mg Fe/kg. Coronal T 2‐W and the T 2*‐W images were obtained before and 4 hours and 6 hours post‐injection. Signal intensity (SI) and relative signal enhancement (RSE) were computed in two‐ and three‐dimensional analyses. Histological analysis of tumors was evaluated, and the Fe distribution within the body based on atomic absorption spectroscopy was calculated.
One‐way ANOVA followed by Tukey's multiple comparison test, Paired‐samples T‐test, P < 0.05 was considered significant.
A reduction in T 2‐W SI was achieved as 22 ± 7%, 59 ± 3%, 65 ± 5%, and 78 ± 3% respectively for BNPs, TBNPs, DNPs, and TDNPs 6 hours post‐injection. The most difference between targeted and non‐targeted groups was observed at 6 hours for PSMA‐11‐HBED, and at 4 hours for PSMA‐11‐HYNIC. RSE indicated 88.6 ± 3.1% and 80.7 ± 3.2% enhanced contrast between tumor and muscle region for TBNPs and TDNPs on T 2*‐W images.